Axsome Therapeutics (AXSM) Misses Q2 EPS by 5c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.06), $0.05 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $6.92 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Axsome Therapeutics (AXSM) PT Lowered to $279 at RBC Capital
• Hour Loop, Inc. (HOUR) Reports Q2 EPS of $0.03
• Immunome, Inc. (IMNM) Reports Q2 Loss of $0.65